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Ⅰ?Introduction
 Peptide ligands have attracted attention as 
powerful molecular tools in the treatment of 
cancer patients?1,2?. Current chemotherapy 
using standard anticancer drugs often leads to 
severe side effects, causing extreme distress 
to the patient. Development of methodologies 
that allow for cancer cell-specific delivery of 
therapeutic agents offers a potential strategy in 
decreasing these harmful and undesirable side 
effects?3,4?.
 Recent studies have shown that peptide 
ligands bound to glucose-regulated protein 78 
?GRP78?can successfully be used for peptide-
based drug delivery?5?. GRP78, a member of 
the HSP70 family, is an endoplasmic reticulum 
?ER?protein that possesses a carboxy?C?
-terminal KDEL sequence that constitutes a 
feedback signal from the Golgi to the ER?6?. 
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SUMMARY
Increased expression of glucose-regulated protein 94?GRP94?on the cell surface is 
associated with tumorigenicity, suggesting that small peptides bound to GRP94 may be useful 
for drug delivery targeted to cancer expressing cell surface GRP94 . In this study, candidate 
peptides that exhibited high affinity binding to the carboxy-terminal fragment of the GRP94 
?GRP94-C? protein were screened using a phage display library. Three high affinity peptides ?No. 
6; CTLMSDPAC, No. 58; CSLVPIPAC, No. 72; CQTKPLFQC?were identified. Kd values for all 
three peptides binding to target GRP94-C protein were within the range of 0.39-0.46 µM. These 
novel peptide sequences could potentially be used as a part of a peptide-conjugated drug system, 
designed to selectively target cancer cells with surface expression of GRP94.
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GRP78 is principally located in the ER; however, 
reports also indicate its existence on the cell 
surface. Expression levels in the ER and on the 
cell surface are both increased under stress 
conditions?7,8?, and high expression levels on 
the cell surface are linked to a greater degree of 
cancer malignancy ?9,10?.
 GRP94, a paralog of HSP90, is also an 
endoplasmic ret iculum?ER?protein that 
possesses peptide and adenine nucleotide-
binding domains. Like other proteins residing 
in the ER, GRP94 contains a C-terminal 
KDEL sequence. GRP94 also exists on the 
cell surface and functions as an antigen-
representing chaperon protein?11?. Increased 
expression of GRP94 on the cell surface has 
also been demonstrated to be associated with 
tumorigenicity?12,13?. 
 In this study, we focused on the discovery 
of GRP94-binding peptides. Since the amino 
?N?-terminal fragment of the GRP94 protein is 
involved in peptide presentation via professional 
antigen presenting cells?14?, it is possible 
that any peptide can bind to this fragment 
sequence-independently. We therefore searched 
for peptides that could bind to the C-terminal 
fragment of the GRP94 protein. 
II．Materials and Methods
Vector Construction
 Full-length GRP94 cDNA?accession no. 
X15187? was amplified using a forward primer
?5'-AAA GGA TCC ATG AGG GCC CTG TGG 
GTG CT-3'? and a reverse primer ?5'-AAA 
GAA TTC TTA TTC AGC TGT AGA TTC 
CT-3'? and inserted into the pGEX-6P-1-GST 
fusion protein expression vector ?GE Healthcare 
UK Limited, Buckinghamshire, UK? to yield 
pGEX-GRP94. The plasmid was further digested 
with BamH1 and HindIII, and a 3.7-kb fragment 
containing the C-terminal domain of GRP94
?amino acids 493 to 799? was re-inserted into 
the empty expression vector pGEX-6P-1 to yield 
pGEX-GRP94-C. 
Purification of recombinant protein
 BL21 competent cells were transformed 
with pGEX-GRP94-C. Transformants were 
cultured in 2?YT medium containing 100 
µg/ml ampicillin at 30?, and fusion protein 
expression was induced using isopropyl-1-thio-
? -D-galactopyranoside ?IPTG?. Glutathione 
S-transferase ?GST? and the C-terminal domain 
of the GRP94 fusion protein ?GST-GRP94-C? 
was bound to a GSTrap FF column ?GE 
Healthcare UK Limited? and further digested 
overnight with PreScission Protease ?GE 
Healthcare Limited, UK? at 4?. The C-terminal 
domain of GRP94 ??37.2 kDa-peptide; GRP94-C? 
was subsequently eluted with a buffer without 
glutathione.
Phage biopanning
 Peptide sequences were selected from a 
commercially available disulfide constrained 
7-mer random library displayed on phage 
M13 via N-terminal fusion to the minor coat 
protein, g3p, with a diversity of 1.3?109 ?Ph. 
D.-C7C ™ phage display peptide library kit, 
New England Biolabs, Beverly, MA, USA?, as 
described previously?15?. Initially, recombinant 
GRP94-C protein was biotinylated using a sulfo-
NHS-LC-biotin ?Pierce, USA? according to 
the manufacturer?s instructions. Biotinylated 
protein ?0.1 µg? and 2?1011 phage particles 
from the Ph. D.-C7CTM phage display peptide 
library kit were mixed in 400 µl of Tris-
buffered saline ?50mM Tris pH 7.5, 150mM 
NaCl? supplemented with 1% ?v/v? Tween-20 
?TBS-T? to prepare the phage-target complex. 
Phage-target complex was then panned against 
a streptavidin-coated plastic plate for affinity 
capture. After washing, bound phages were 
eluted with 1mM dithiothreitol ?DTT? and 
amplified for next-round panning. After a third 
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round of amplification and panning for binding 
GRP94-C protein, individual phages were 
isolated and the displayed peptide sequences 
were deduced after DNA sequencing.
Enzyme-linked immunosorbent assay ?ELISA? 
for binding of selected phages to GRP94-C
 Candidates were selected for the ELISA 
assay based on amino acid similarity. Ninety-
six-well microtiter plates ?Nunc Maxisorp, 
Denmark? were coated with 200 µl per well of 
GRP94-C protein ?100 µg/ml?. 0.1 M NaHCO3 
?pH 8.6? and incubated overnight at 4?. After 
washing with TBS-T, wells were incubated with 
filter-sterilized blocking buffer ?0.1 M NaHCO3 
pH 8.6, 5mg/ml bovine serum albumin, 0.02% 
NaN3? to reduce any non-specific interaction 
of phages to the plate. Fourfold-serially diluted 
samples of selected phages were then placed 
in ELISA microplates and incubated for 2 
h at room temperature. After the unbound 
phages were removed by washing with TBS-T, 
a horseradish peroxidase ?HRP?-conjugated 
anti-M13 antibody ?GE Healthcare Limited? 
diluted with blocking buffer at a ratio of 1:5000 
was added to the plates and incubated for 
1h at room temperature. Immune complexes 
were then detected using 2 ,  2 ' -azino-di -
?3-ethylbenzthiazoline sulfonate? diammonium 
salt ?Roche, Berlin, Germany? as a substrate 
for HRP. After a 20-min incubation at room 
temperature, the absorbance at 405 nm was 
determined using an automated 
ELISA reader  ?Mode l  E -max , 
Molecular Devices ,  CA, USA?. 
From the pool of candidate peptides 
?Table 1?, a single randomly selected 
peptide ?peptide No.34? with a lower 
or no amino acid similarity to the 
above selected peptides was used as 
a negative control under identical 
experimental conditions.
Peptide biotinylation
 Cysteine-constrained peptides 
with biotinylated amino termini 
were purchased from Scrum Co. 
Ltd. ?Tokyo, Japan?. Intra-molecular 
disulfide bridge formation of the 
peptides was characterized using 
matrix-assisted laser desorption/
i on i za t i on  t ime -o f - f l i gh t  mass 
spectroscopy before and after 
reduction using 1mM DTT and also 
by their unreactivity to Ellman?s 
reagent, a sulfhydryl assay reagent 
?Pierce, IL, USA?.
Phage 1 C P S W R Q V A C
Phage 2 C M T H R F P S C
Phage 3 C L P H T R L E C
Phage 4 C Q K L P Y K Q C
Phage 5 C T S L H N W P C
Phage 6 C T L M S D P A C
Phage 7 C Q N H A P L E C
Phage 8 C P L Q M L Y N C
Phage 9 C L E A T Y T Y C
Phage 10 C T S K H H Q A C
Phage 11 C R L D S P E Y C
Phage 12 C R L V S D G A C
Phage 13 C N L G V H N H C
Phage 15 C N A T A Q W L C
Phage 16 C T P T L P S S C
Phage 17 C E M R M L P R C
Phage 18 C T S S G A P K C
Phage 19 C I T P L Q T W C
Phage 20 C N T Y E P H N C
Phage 21 C T L K E T Q H C
Phage 22 C A T T T Q A N C
Phage 23 C P N S D A Y S C
Phage 24 C D T N Q K I L C
Phage 25 C S F N L E N H C
Phage 26 C H V A L H K K C
Phage 27 C P A T K T T H C
Phage 28 C S T L L S T T C
Phage 29 C T P N T D R F C
Phage 30 C L E S P K R L C
Phage 31 C H G T I A P Q C
Phage 32 C L A S S W L R C
Phage 33 C V Y R S H I P C
Phage 34 C Y M W H N K N C
Phage 35 C F P T R P A S C
Phage 36 C S M K Q L Q M C
Phage 37 C P P M I T R Y C
Phage 38 C T A F P P I T C
Phage 39 C K S M N P P L C
Phage 40 C S S G H L R L C
Phage 41 C S T P R D L R C
Phage 42 C S D W Q T K V C
Phage 43 C S L P L N M H C
Phage 44 C P D S M T N S C
Phage 45 C L R M T N Q L C
Phage 46 C I P R W M M T C
Phage 48 C A T L S H P T C
Phage 49 C P S K L V L N C
Phage 52 C H A T Q L H S C
Phage 53 C D M A A P S A C
Phage 54 C H G M G A L P C
Phage 55 C P E M R Q Q S C
Phage 56 C K T L P L Q S C
Phage 57 C Q K T A W G Q C
Phage 58 C S L V P I P A C
Phage 59 C L H L S K N S C
Phage 60 C P L L P D K Q C
Phage 61 C S S D V S P S C
Phage 62 C K P S S Y P A C
Phage 63 C V R T T M S H C
Phage 64 C Q H L W Y Q S C
Phage 66 C E N P R P S A C
Phage 67 C G L G S K L P C
Phage 68 C L L H T A F S C
Phage 69 C K A N S P S L C
Phage 70 C Q Y G R D A D C
Phage 71 C V L S S L F Q C
Phage 72 C Q T K P L F Q C
Phage 75 C P L S R L L P C
Phage 76 C W G S N T F W C
Phage 77 C L R A Q F N I C
Phage 78 C S A A C Y D S C
Phage 79 C T L P S H G T C
Phage 80 C S M T A R P Q C
Phage 
clone No.
Phage 
clone No.
Peptide sequence Peptide sequence
Table 1. Amino acid sequences of 80 phage clones randomly selected after third 
round of biopannning with GRP94-C protein.
Note: Seven phage clones (clone Nos. 14, 47, 50, 51, 65, 73, and 74) were removed from the table since 
they had a truncated or duplicated peptide sequence.
Table 1 Amino acid sequences of 80 phage clones 
randomly  selected after third round of 
biopannning with GRP94-C protein
64 Muhammed Zahed et al.
Quartz Crystal Microbalance ?QCM? analysis
 Binding analysis of the interaction between 
GRP94-C and synthetic peptides was performed 
with a 27 MHz QCM machine ?Affinix Q4, 
Tokyo, Japan?. Briefly, the sensor chip was 
initially cleaned twice with 1% SDS solution and 
rinsed with phosphate-buffered saline ?PBS, 150 
mM NaCl in 10 mM phosphate buffer, pH 7.2?. 
Neutravidin ?10 µg/ml? was then absorbed 
onto the chip for immobilization of biotinylated 
peptides. Biotinylated peptide solution ?10 µM? 
was further added to the neutravidin-absorbed 
sensor chip for one hour at room temperature. 
Final ly ,  GRP94-C prote in was added to 
the peptide-immobilized chip at different 
concentrations for binding measurements and 
the Kd value was calculated. Purified GST 
protein was used as a negative control under 
identical experimental conditions.
Ⅲ．Results
Selection of GRP94-binding Phage by Phage 
display:
 To screen peptide ligands for the GRP94-C 
protein, we used a phage display peptide 
library displaying 7-mer cysteine constrained 
random peptides ?C-X7-C?. During the course 
of selection, the relative yield of phage recovery 
improved from 0.000005 ?f irst round? to 
0.0001 ?third round?, which is consistent with 
enrichment in binding clones. After three 
rounds of panning using purified GRP94-C 
protein, 80 phage clones were randomly 
selected, amplified and sequenced to identify the 
displayed peptides. Primarily from the pool of 80 
candidate peptides ?Table 1?, 16 different phage 
peptide sequences were selected and arranged 
into four groups based on amino acid sequence 
or consensus motif similarity ?Fig. 1?. 
Confirmation of phage binding to GRP94-C by 
ELISA 
 Phage ELISA experiments were performed 
to test the specific binding of peptides to the 
target GRP94-C protein. The 16 phages selected 
?Fig. 1? were individually amplified, serially 
diluted and incubated with purified recombinant 
GRP94-C target protein, and a randomly selected 
phage was investigated in parallel as a negative 
control. Fourteen phages ?excluding phage No. 
21 and 35? showed increased absorbance values 
in the presence of the target protein when 
compared with the negative control ?Fig. 2?. We 
chose eight clones ?phage Nos. 4, 6, 18, 58, 60, 
66, 72 and 79? that showed the greatest increase 
in reactivity using the first ELISA. We further 
performed phage ELISA analyses to confirm 
Fig. 1
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Fig. 1?Grouping of candidates for GRP94-C binding 
peptides based on amino acid sequence 
consensus. Peptide sequences were grouped 
into four groups based on the analogous 
positions of similar amino acid residues 
?boxed residues?. The four groups are as 
follows: group 1 ?peptide Nos. 6, 11, 12, 58, 79? 
group 2 ?peptide Nos. 5, 10, 18, 21?, group 3 
?peptide Nos. 19, 35, 66? and group 4 ?peptide 
Nos. 4, 57, 60, 72?.
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showed a similar absorbance range and thus, 
were expected to bind to GRP94-C with a 
similar affinity range.
QCM Analysis
 Binding affinity of the selected three 
peptides ?peptide Nos. 6, 58 and 72? with 
GRP94-C protein was measured by QCM 
analysis. Protein binding to the immobilized 
peptide was calculated based on the Sauerbrey 
equation?16?,  which represents a l inear 
dependence between frequency shift and the 
bound GRP94-C protein. Binding of the target 
GRP94-C protein to the peptides immobilized 
on the QCM sensor chip was observed as a 
decreased frequency ?Fig. 5A?. Addition of 
purified GST protein did not produce a shift in 
frequency and suggested that the GST proteins 
did not bind to the immobilized peptides ?Fig. 
5A?. The affinity constant ?Kd? value was 
determined by plotting absorbed GRP94-C 
protein in terms of frequency shift ?∆F? versus 
the binding strength of phage-borne peptides 
to GRP94-C protein ?Fig. 3?. Four of the eight 
phage clones ?phage Nos. 6, 58, 60 and 72? 
were selected based on their binding activity 
to GRP94-C and ranked on the basis of the 
final ELISA results. The best three candidates 
?phage Nos. 6, 58 and 72, Fig. 4? were chosen 
for downstream experiments. All three phages 
Fig. 2
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Fig. 2?Result of first ELISA for 16 selected phage 
clones. Each phage clone was diluted 12 
times ?fourfold serial dilutions starting with 
1012 virions?, and absorbance was read at 
405 nm by microplate reader. Eight phage 
clones were selected for the second ELISA 
experiment ?boxed numbers? on the basis of 
absorbance intensity.
Fig. 3?Result of second ELISA assay for eight 
selected phage clones. Each phage clone 
was serially diluted seven times ?fourfold 
serial dilutions starting with 1012 virions?, 
and absorbance at 405 nm was determined 
using a microplate reader. Four phage clones 
?boxed numbers? were selected for further 
ELISA experiments to check reproducibility.
Fig. 3
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Fig. 4?Interaction of four selected phage clones with 
GRP94-C analyzed by ELISA. Each phage 
clone was serially diluted six times ?fourfold 
serial dilutions starting with 1012 virions? and 
absorbance at 405 nm was determined using 
a microplate reader. Three phage clones were 
selected ?phage clone Nos. 6, 58 and 72? on 
the basis of their levels of absorbance.
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to healthy tissues present major obstacles in 
the development of new therapeutic anticancer 
drugs. Discovery of functional ligand-receptor 
systems is one of the critical steps toward the 
development of an efficient cancer therapy. 
Recently, several studies have suggested that 
proteins selectively expressed on the surface of 
cancer cells are potentially useful targets for the 
development of novel anticancer therapies?5, 
17?. 
 Previous studies have shown that the 
GRP94 chaperon protein is expressed on the 
cell surface in some cancer cells but not in non-
transformed cells?12?. Characteristics of cell 
surface expression of GRP94 have however 
received much less attention, since it is widely 
considered to be a chaperon in immune 
signaling and peptide presentation for antigen 
representing cells?18?. In the present study, 
we focused on cell surface expression of GRP94 
as a target for a peptide-drug conjugate. As a 
first step, we screened GRP94 protein-binding 
peptides using a phage display technique. The 
C-terminal domain of GRP94 protein was chosen 
to avoid non-specific, physiological peptide 
binding of the N-terminal domain?14?. Initially, 
16 peptides were selected from the phage 
display-derived pool of candidate peptides and 
divided into four groups based on their amino 
acid similarity ?Fig. 1?. Threonine, proline and 
leucine amino acid residues were frequently 
found in the peptide sequences for each of the 
four groups and these may play a role in GRP94 
protein binding. 
 Three peptides ?peptide Nos. 6, 58 and 72? 
out of the above-mentioned 16 candidates were 
selected based on their higher absorbance at 
405 nm using multiple ELISAs and gave values 
within a similar range ?absorbance reading 1.3-
1.6 at 405 nm?. QCM analysis revealed a high 
affinity of these peptides to GRP94-C protein. Kd 
values for the binding of all three peptides to 
GRP94 were within a similar range of 0.39-0.46 
the concentration of injected GRP94-C in the 
buffer solution ?Fig. 5B?. Kd values for all three 
peptides ?peptide Nos. 6, 58 and 72? binding to 
target GRP94-C protein were within the range 
of 0.39-0.46 µM ?0.45 µM, 0.46 µM and 0.39 µM, 
respectively?. No significant difference in the 
binding affinity of these peptides to GRP94-C 
was observed, although peptide No. 72 did show 
a slightly higher binding affinity.
Ⅳ．Discussion
 Low bioavailability and nonspecific toxicity 
1.0 2.0 3.0 4.00
0
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GRP94-C protein (mM)
-D
F(
Hz
)
120 240 360 4800
Time (sec)
DF
(H
z)
0
-120
-80
-40
A
B
Fig. 5
Fig. 5?QCM analysis. ?A? Typical time-course plots 
of the Frequency changes ??F? after addition 
of GRP94-C protein ?solid line? or GST protein 
?dot-line? to peptide No.6 ?black?, No.58 ?red? 
or No.72?blue?-immobilized in cells in 27-
MHz quartz plates. Proteins were added to 
the cells at the concentration of 250 nmol/L. 
Data are from one representative experiment 
out of at least three performed. ?B? Plots of 
?F at equilibrium against the concentration 
of GRP94-C protein. DF responding to the 
addition of GRP94 to peptide No.6, No.58 and 
No.72-immobilized in plated cells are plotted 
with black, red, and blue lines, respectively.
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